Do analysts recommend STX or ANCR?

Shield Therapeutics currently has a consensus price target of GBX 15, indicating a potential upside of 221.89%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Shield Therapeutics is more favorable than Animalcare Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Animalcare Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate BVXP or STX?

Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 221.89%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than Bioventix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts rate VLG or STX?

Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 221.89%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than Venture Life Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venture Life Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend ORPH or STX?

Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 221.89%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Shield Therapeutics is more favorable than Open Orphan. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Open Orphan 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shield Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, ORPH or STX?

Open Orphan has higher earnings, but lower revenue than Shield Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Open Orphan £34.71M 0.00 N/A N/A N/A Shield Therapeutics £58.63M 0.85 -£36.28M -£1.00 N/A

Shield Therapeutics (STX) Competitors

GBX 4.66 -0.24 (-4.90%)

As of 09/11/2026 11:58 AM Eastern

Compare

STX vs. ANCR, BVXP, VLG, ORPH, and EAH

Should you buy Shield Therapeutics stock or one of its competitors? Shield Therapeutics's main competitors and comparable companies include Animalcare Group (ANCR), Bioventix (BVXP), Venture Life Group (VLG), Open Orphan (ORPH), and ECO Animal Health Group (EAH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Shield Therapeutics compare to Animalcare Group?

Shield Therapeutics (LON:STX) and Animalcare Group (LON:ANCR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Animalcare Group has higher revenue and earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£58.63M	0.85	-£36.28M	-£1.00	N/A
Animalcare Group	£89.11M	2.60	£36.55M	£7.30	45.89

Animalcare Group has a net margin of 5.70% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Animalcare Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-17.76%	64.57%	-47.85%
Animalcare Group	5.70%	4.46%	2.97%

6.7% of Shield Therapeutics shares are held by institutional investors. Comparatively, 14.3% of Animalcare Group shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by insiders. Comparatively, 30.1% of Animalcare Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Shield Therapeutics' average media sentiment score of 0.00 equaled Animalcare Group'saverage media sentiment score.

Company	Overall Sentiment
Shield Therapeutics	Neutral
Animalcare Group	Neutral

Shield Therapeutics has a beta of 1.768, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Animalcare Group has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Shield Therapeutics currently has a consensus price target of GBX 15, indicating a potential upside of 221.89%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Shield Therapeutics is more favorable than Animalcare Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Animalcare Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Animalcare Group beats Shield Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Shield Therapeutics compare to Bioventix?

Bioventix (LON:BVXP) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Bioventix has a net margin of 59.30% compared to Shield Therapeutics' net margin of -17.76%. Bioventix's return on equity of 65.83% beat Shield Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventix	59.30%	65.83%	54.07%
Shield Therapeutics	-17.76%	64.57%	-47.85%

Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 221.89%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than Bioventix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Bioventix had 1 more articles in the media than Shield Therapeutics. MarketBeat recorded 1 mentions for Bioventix and 0 mentions for Shield Therapeutics. Bioventix's average media sentiment score of 0.75 beat Shield Therapeutics' score of 0.00 indicating that Bioventix is being referred to more favorably in the media.

Company	Overall Sentiment
Bioventix	Positive
Shield Therapeutics	Neutral

Bioventix has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventix	£12.54M	6.67	£8.12M	£140.52	11.39
Shield Therapeutics	£58.63M	0.85	-£36.28M	-£1.00	N/A

Bioventix has a beta of 0.555, meaning that its share price is 45% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.768, meaning that its share price is 77% more volatile than the broader market.

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Bioventix beats Shield Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Shield Therapeutics compare to Venture Life Group?

Venture Life Group (LON:VLG) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Venture Life Group's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company	Overall Sentiment
Venture Life Group	Neutral
Shield Therapeutics	Neutral

Venture Life Group has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venture Life Group	£35.17M	2.32	£747.21K	£4.37	15.54
Shield Therapeutics	£58.63M	0.85	-£36.28M	-£1.00	N/A

Shield Therapeutics has a consensus price target of GBX 15, indicating a potential upside of 221.89%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than Venture Life Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venture Life Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

21.9% of Venture Life Group shares are owned by institutional investors. Comparatively, 6.7% of Shield Therapeutics shares are owned by institutional investors. 7.5% of Venture Life Group shares are owned by company insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Venture Life Group has a net margin of 17.42% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Venture Life Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venture Life Group	17.42%	7.82%	1.56%
Shield Therapeutics	-17.76%	64.57%	-47.85%

Venture Life Group has a beta of 0.234, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Shield Therapeutics has a beta of 1.768, suggesting that its share price is 77% more volatile than the broader market.

Summary

Venture Life Group beats Shield Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Shield Therapeutics compare to Open Orphan?

Open Orphan (LON:ORPH) and Shield Therapeutics (LON:STX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Open Orphan has a net margin of 0.00% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat Open Orphan's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Open Orphan	N/A	N/A	N/A
Shield Therapeutics	-17.76%	64.57%	-47.85%

6.7% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 221.89%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Shield Therapeutics is more favorable than Open Orphan.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Open Orphan	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Open Orphan has higher earnings, but lower revenue than Shield Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Open Orphan	£34.71M	0.00	N/A	N/A	N/A
Shield Therapeutics	£58.63M	0.85	-£36.28M	-£1.00	N/A

In the previous week, Open Orphan's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score.

Company	Overall Sentiment
Open Orphan	Neutral
Shield Therapeutics	Neutral

Summary

Shield Therapeutics beats Open Orphan on 8 of the 10 factors compared between the two stocks.

How does Shield Therapeutics compare to ECO Animal Health Group?

Shield Therapeutics (LON:STX) and ECO Animal Health Group (LON:EAH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Shield Therapeutics presently has a consensus price target of GBX 15, suggesting a potential upside of 221.89%. ECO Animal Health Group has a consensus price target of GBX 160, suggesting a potential upside of 65.36%. Given Shield Therapeutics' higher possible upside, equities research analysts clearly believe Shield Therapeutics is more favorable than ECO Animal Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ECO Animal Health Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Shield Therapeutics has a beta of 1.768, indicating that its share price is 77% more volatile than the broader market. Comparatively, ECO Animal Health Group has a beta of 0.701, indicating that its share price is 30% less volatile than the broader market.

ECO Animal Health Group has a net margin of 2.50% compared to Shield Therapeutics' net margin of -17.76%. Shield Therapeutics' return on equity of 64.57% beat ECO Animal Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-17.76%	64.57%	-47.85%
ECO Animal Health Group	2.50%	2.55%	2.14%

ECO Animal Health Group has higher revenue and earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than ECO Animal Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£58.63M	0.85	-£36.28M	-£1.00	N/A
ECO Animal Health Group	£87.53M	0.74	£1.05M	£3.15	30.72

6.7% of Shield Therapeutics shares are owned by institutional investors. Comparatively, 40.6% of ECO Animal Health Group shares are owned by institutional investors. 3.0% of Shield Therapeutics shares are owned by insiders. Comparatively, 11.3% of ECO Animal Health Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, ECO Animal Health Group had 1 more articles in the media than Shield Therapeutics. MarketBeat recorded 1 mentions for ECO Animal Health Group and 0 mentions for Shield Therapeutics. ECO Animal Health Group's average media sentiment score of 0.46 beat Shield Therapeutics' score of 0.00 indicating that ECO Animal Health Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Shield Therapeutics	Neutral
ECO Animal Health Group	Neutral

Summary

ECO Animal Health Group beats Shield Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Shield Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STX vs. The Competition

Export

Metric	Shield Therapeutics	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£49.86M	£12.46B	£7.16B	£2.87B
Dividend Yield	N/A	2.62%	2.56%	6.23%
P/E Ratio	-4.66	799.74	274.10	366.83
Price / Sales	0.85	763.35	656.00	83,599.70
Price / Cash	6.36	89.25	77.04	27.89
Price / Book	85.15	10.39	10.33	6.33
Net Income	-£36.28M	£2.85B	£3.50B	£5.89B
7 Day Performance	-13.91%	-3.70%	-3.35%	-0.69%
1 Month Performance	10.82%	0.78%	-0.43%	0.18%
1 Year Performance	-48.22%	3.48%	19.21%	20.03%

Shield Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STX Shield Therapeutics	1.2306 of 5 stars	GBX 4.66 -4.9%	GBX 15 +221.9%	-43.2%	£49.86M	£58.63M	N/A	40,000	Gap Down
ANCR Animalcare Group	N/A	GBX 335 flat	N/A	N/A	£231.30M	£89.11M	45.89	220
BVXP Bioventix	N/A	GBX 1,754 +1.4%	N/A	-34.7%	£90.39M	£12.54M	12.48	12	News Coverage Gap Down
VLG Venture Life Group	N/A	GBX 66 flat	N/A	+15.1%	£79.49M	£35.17M	15.10	165
ORPH Open Orphan	N/A	N/A	N/A	N/A	£67.09M	£34.71M	N/A	179

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:STX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shield Therapeutics (STX) Competitors

STX vs. ANCR, BVXP, VLG, ORPH, and EAH

How does Shield Therapeutics compare to Animalcare Group?

Summary

How does Shield Therapeutics compare to Bioventix?

Summary

How does Shield Therapeutics compare to Venture Life Group?

Summary

How does Shield Therapeutics compare to Open Orphan?

Summary

How does Shield Therapeutics compare to ECO Animal Health Group?

Summary

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shield Therapeutics (STX) Competitors

STX vs. ANCR, BVXP, VLG, ORPH, and EAH

How does Shield Therapeutics compare to Animalcare Group?

Which has better earnings & valuation, STX or ANCR?

Is STX or ANCR more profitable?

Do institutionals and insiders hold more shares of STX or ANCR?

Does the media prefer STX or ANCR?

Which has more volatility & risk, STX or ANCR?

Do analysts recommend STX or ANCR?

Summary

How does Shield Therapeutics compare to Bioventix?

Is BVXP or STX more profitable?

Do analysts rate BVXP or STX?

Does the media prefer BVXP or STX?

Which has higher valuation & earnings, BVXP or STX?

Which has more volatility & risk, BVXP or STX?

Do insiders & institutionals believe in BVXP or STX?

Summary

How does Shield Therapeutics compare to Venture Life Group?

Does the media refer more to VLG or STX?

Which has preferable valuation and earnings, VLG or STX?

Do analysts rate VLG or STX?

Do institutionals & insiders believe in VLG or STX?

Is VLG or STX more profitable?

Which has more volatility & risk, VLG or STX?

Summary

How does Shield Therapeutics compare to Open Orphan?

Is ORPH or STX more profitable?

Do institutionals and insiders believe in ORPH or STX?

Do analysts recommend ORPH or STX?

Which has stronger earnings & valuation, ORPH or STX?

Does the media favor ORPH or STX?

Summary

How does Shield Therapeutics compare to ECO Animal Health Group?

Do analysts prefer STX or EAH?

Which has more risk & volatility, STX or EAH?

Is STX or EAH more profitable?

Which has preferable valuation & earnings, STX or EAH?

Do insiders & institutionals hold more shares of STX or EAH?

Does the media prefer STX or EAH?

Summary

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools